Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401

Journal of Clinical Oncology

Volumn 30, Issue 13, 2012, Pages 1534-1540

  Kelly, William Kevin ^a   Halabi, Susan ^b   Carducci, Michael ^d   George, Daniel ^b   Mahoney, John F ^c   Stadler, Walter M ^e   Morris, Michael ^f   Kantoff, Philip ^g   Monk, J Paul ^h   Kaplan, Ellen ^b   Vogelzang, Nicholas J ⁱ   Small, Eric J ^j  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c CAROLINAS MEDICAL CENTER   (United States)

^d JOHNS HOPKINS UNIVERSITY   (United States)

^e UNIVERSITY OF CHICAGO   (United States)

^f MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^g DANA FARBER CANCER INSTITUTE   (United States)

^h OHIO STATE UNIVERSITY   (United States)

ⁱ Developmental Therapeutics Committee and Co Chair of the Genitourinary Committee   (United States)

^j UNIVERSITY OF CALIFORNIA   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; DOCETAXEL; PLACEBO; PREDNISONE; PROSTATE SPECIFIC ANTIGEN; ANTIANDROGEN; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; MONOCLONAL ANTIBODY; TAXOID;

ADULT; AGED; ANEMIA; ARTICLE; BONE MARROW; BRAIN ISCHEMIA; CALICIVIRUS INFECTION; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; CLOSTRIDIUM DIFFICILE INFECTION; COLITIS; COMPARATIVE STUDY; CONTROLLED STUDY; DEHYDRATION; DIGESTIVE SYSTEM PERFORATION; DISEASE COURSE; DOUBLE BLIND PROCEDURE; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; EMBOLISM; FEBRILE NEUTROPENIA; GRANULOCYTE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; HYPERTENSION; INFECTION; KIDNEY FUNCTION; LEFT VENTRICULAR DIASTOLIC DYSFUNCTION; LEFT VENTRICULAR SYSTOLIC DYSFUNCTION; LEUKOCYTE; LIVER FUNCTION; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; NAUSEA; NEUTROPHIL; OVERALL SURVIVAL; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STOMATITIS; THROMBOSIS; THROMBUS; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; WEIGHT REDUCTION; ADENOCARCINOMA; BLOOD; CHI SQUARE DISTRIBUTION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG RESISTANCE; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; PATHOLOGY; PHASE 3 CLINICAL TRIAL; PROSTATE TUMOR; RISK; RISK ASSESSMENT; RISK FACTOR; TIME; UNITED STATES;

ADENOCARCINOMA; AGED; ANDROGEN ANTAGONISTS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHI-SQUARE DISTRIBUTION; DISEASE-FREE SURVIVAL; DOUBLE-BLIND METHOD; DRUG RESISTANCE, NEOPLASM; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; ODDS RATIO; PLACEBOS; PREDNISONE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RISK ASSESSMENT; RISK FACTORS; TAXOIDS; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES;

EID: 84861690508     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.39.4767     Document Type: Article

References (21)

1. Ferrer FA, Miller LJ, Lindquist R, et al: Expression of vascular endothelial growth factor receptors in human prostate cancer. Urology 54:567-572, 1999
2. Weidner N, Carroll PR, Flax J, et al: Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol 143:401-409, 1993
3. Ferrer FA, Miller LJ, Andrawis RI: Vascular endothelial growth factor (VEGF) expression in human prostate cancer: In situ and in vitro expression of VEGF by human prostate cancer cells. J Urol 157:2329-2333, 1997
4. Duque JL, Loughlin KR, Adam RM, et al: Plasma levels of vascular endothelial growth factor are increased in patients with metastatic prostate cancer. Urology 54:523-527, 1999
5. Duque JL, Loughlin KR, Adam RM, et al: Measurement of plasma levels of vascular endothelial growth factor in prostate cancer patients: Relationship with clinical stage, Gleason score, prostate volume, and serum prostate-specific antigen. Clinics (Sao Paulo) 61:401-408, 2006
6. Bok RA, Halabi S, Fei DT, et al: Vascular endothelial growth factor and and basic fibroblast growth factor urine levels as predictors of outcome in hormone-refractory prostate cancer patients: A Cancer and Leukemia Group B study. Cancer Res 61:2533-2536, 2001
7. George DJ, Halabi S, Shepard TF, et al: The prognostic significance of plasma interleukin-6 levels in patients with metastatic hormone-refractory prostate cancer: Results from Cancer and Leukemia Group B 9480. Clin Cancer Res 11:1815-1820, 2005
8. Picus J, Halabi S, Kelly WW, et al: A phase II study of estramustine, docetaxel, and bevacizumab in men with castration resistant prostate cancer: Results of Cancer and Leukemia Group B (CALGB) 90006. Cancer 117:526-533, 2011
9. Bubley GJ, Carducci M, Dahut W, et al: Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: Recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol 17:3461-3467, 1999
10. Halabi S, Small EJ, Kantoff PW, et al: Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. J Clin Oncol 21:1232-1237, 2003
11. Smith TJ, Khatcheressian J, Lyman GH, et al: 2006 update of recommendations for the use of white blood cell growth factors: An evidence-based clinical practice guideline. J Clin Oncol 24:3187-3205, 2006
12. Berthold DR, Pond GR, Soban F, et al: Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: Updated survival in the TAX 327 study. J Clin Oncol 26:242-245, 2008
13. Burger RA, Brady MF, Bookman MA, et al: Phase III trial of bevacizumab (BEV) in the primary treatment of advanced epithelial ovarian cancer (EOC), primary peritoneal cancer (PPC), or fallopian tube cancer (FTC): A Gynecologic Oncology Group study. J Clin Oncol 28:6s, 2010 (suppl: abstr LBA1)
14. Miller K, Wang M, Gralow J, et al: Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 357:2666-2676, 2007
15. Gray R, Bhattacharya S, Bowden C, et al: Independent review of E2100: A phase III trial of bevacizumab plus paclitaxel versus paclitaxel in women with metastatic breast cancer. J Clin Oncol 27:4966-4972, 2009
16. Sandler A, Yi J, Dahlberg S, et al: Treatment outcomes by tumor histology in Eastern Cooperative Group Study E4599 of bevacizumab with paclitaxel/carboplatin for advanced non-small cell lung cancer. J Thorac Oncol 5:1416-1423, 2010
17. Hurwitz H, Fehrenbacher L, Novotny W, et al: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335-2342, 2004
18. Kozloff MF, Berlin J, Flynn PJ, et al: Clinical outcomes in elderly patients with metastatic colorectal cancer receiving bevacizumab and chemotherapy: Results from the BRiTE observational cohort study. Oncology 78:329-339, 2010
19. Franke RM, Carducci MA, Rudek MA, et al: Castration-dependent pharmacokinetics of docetaxel in patients with prostate cancer. J Clin Oncol 28:4562-4567, 2010
20. Escudier B, Pluzanska A, Koralewski P, et al: Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: A randomised, double-blind phase III trial. Lancet 370:2103-2111, 2007
21. Rini BI, Halabi S, Rosenberg JE, et al: Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: Final results of CALGB 90206. J Clin Oncol 28:2137-2143, 2010